Open AccessEvidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)
Author(s) -
Naveen Pemmaraju,
Ruben A. Mesa
Publication year - 2015
Publication title -
hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.321
H-Index - 91
eISSN - 1520-4391
pISSN - 1520-4383
DOI - 10.1182/asheducation-2015.1.649
Subject(s) - polycythemia vera , myelofibrosis , medicine , janus kinase 2 , janus kinase , hematology , ruxolitinib , myeloproliferative disorders , international prognostic scoring system , oncology , bone marrow , myelodysplastic syndromes , cytokine , receptor
A 69-year-old man presents with a Dynamic International Prognostic Scoring System (DIPSS) intermediate-risk 2 post polycythemia vera myelofibrosis with significant splenomegaly, 30 pound weight loss, constitutional symptoms, and 2% peripheral blood blasts. He has no other significant past medical history and no other major comorbid conditions. You are asked by the hematology fellow you are supervising whether or not treating this patient with a Janus kinase (JAK) inhibitor will decrease major morbid events.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom